DOJ Orders Crackdown on Birth Tourism After Supreme Court Upholds Birthright Citizenship 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Amy Coney Barrett Faces Conservative Backlash After Key Supreme Court Rulings Against Trump 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Trinidad Businessman Dominic Hadeed Appeals Detention Over Alleged Assassination Plot 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
US Supreme Court Strikes Down Hawaii Gun Carry Law on Private Property 
Sara Duterte Impeachment Trial Opens, Putting 2028 Philippine Election in Focus 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Should I take zinc or eat oysters to ward off colds, boost my immune system or improve fertility? 
DOJ Seeks Dismissal of Fraud Charges Against Gautam Adani in U.S. Court 
UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
Moderna has reached a major legal settlement worth up to $2.25 billion with Genevant Sciences and Arbutus Biopharma, ending a long-running patent dispute over the lipid nanoparticle (LNP) technology used in its COVID-19 vaccine. The agreement resolves multiple lawsuits accusing Moderna of using the companies’ LNP delivery system without authorization in its mRNA-based vaccine.
Under the terms of the settlement, Moderna will pay $950 million upfront in July 2026. An additional $1.3 billion may be paid depending on the outcome of a separate legal appeal. The deal brings closure to both U.S. and international legal actions related to the disputed vaccine technology.
Lipid nanoparticles play a critical role in mRNA vaccines, including Moderna’s COVID-19 shot. The technology acts as a protective carrier that shields fragile messenger RNA molecules and helps deliver them safely into human cells, enabling the vaccine to trigger an immune response. Genevant and Arbutus claimed ownership of key patents covering this LNP delivery system and argued that Moderna used the technology without proper licensing.
As part of the settlement, Moderna stated it will not owe royalties to Genevant or Arbutus for LNP technology in its future vaccine products. This clause removes potential financial uncertainty for the biotech company as it continues developing new vaccines, including updated COVID-19 shots and combination COVID/flu vaccines.
Investors reacted positively to the announcement. Moderna shares surged more than 10% in after-hours trading following the news. Arbutus Biopharma stock climbed approximately 11%, while Roivant Sciences, Genevant’s parent company, saw a modest gain of about 1%.
Analysts believe the settlement removes a significant legal risk for Moderna. According to Jefferies analyst Andrew Tsai, the agreement eliminates the worst-case scenario of paying double-digit royalty rates on vaccine sales. Considering Moderna has generated roughly $48 billion in global COVID-19 vaccine revenue, the settlement amount represents only a small fraction of those earnings.
The case had been scheduled to go to trial in Delaware federal court, marking what would have been the first major trial among several high-stakes patent disputes tied to COVID-19 vaccine technology. Similar lawsuits involving Pfizer and BioNTech remain ongoing, highlighting the intense competition and intellectual property battles within the rapidly evolving mRNA vaccine industry.
